These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29461919)

  • 21. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults.
    Lal H; Zahaf T; Heineman TC
    Hum Vaccin Immunother; 2013 Jul; 9(7):1425-9. PubMed ID: 23584252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
    Lal H; Cunningham AL; Godeaux O; Chlibek R; Diez-Domingo J; Hwang SJ; Levin MJ; McElhaney JE; Poder A; Puig-Barberà J; Vesikari T; Watanabe D; Weckx L; Zahaf T; Heineman TC;
    N Engl J Med; 2015 May; 372(22):2087-96. PubMed ID: 25916341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
    Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
    J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.
    Lee SJ; Park HJ; Ko HL; Lee JE; Lee HJ; Kim H; Nam JH
    Immun Inflamm Dis; 2020 Jun; 8(2):216-227. PubMed ID: 32167678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice.
    Li D; Bian L; Cui L; Zhou J; Li G; Zhao X; Xing L; Cui J; Sun B; Jiang C; Kong W; Zhang Y; Chen Y
    Int J Nanomedicine; 2024; 19():8029-8042. PubMed ID: 39130684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
    Yao CA; Chen LK; Huang KC
    Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
    Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
    Boutry C; Hastie A; Diez-Domingo J; Tinoco JC; Yu CJ; Andrews C; Beytout J; Caso C; Cheng HS; Cheong HJ; Choo EJ; Curiac D; Di Paolo E; Dionne M; Eckermann T; Esen M; Ferguson M; Ghesquiere W; Hwang SJ; Avelino-Silva TJ; Kosina P; Liu CS; Markkula J; Moeckesch B; Murta de Oliveira C; Park DW; Pauksens K; Pirrotta P; Plassmann G; Pretswell C; Rombo L; Salaun B; Sanmartin Berglund J; Schenkenberger I; Schwarz T; Shi M; Ukkonen B; Zahaf T; Zerbini C; Schuind A; Cunningham AL;
    Clin Infect Dis; 2022 Apr; 74(8):1459-1467. PubMed ID: 34283213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
    N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults.
    van der Heiden M; de Rond LGH; van Zelm MC; Berbers GAM; Boots AMH; Buisman AM
    Front Immunol; 2018; 9():46. PubMed ID: 29410671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vaccines against varicella-zoster virus (VZV)].
    Salleras L; Salleras M; Soldevila N; Prat A; Garrido P; Domínguez Á
    Enferm Infecc Microbiol Clin; 2015; 33(6):411-23. PubMed ID: 26096575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.
    Bharucha T; Ming D; Breuer J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1789-1797. PubMed ID: 28426274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.
    Beals CR; Railkar RA; Schaeffer AK; Levin Y; Kochba E; Meyer BK; Evans RK; Sheldon EA; Lasseter K; Lang N; Weinberg A; Canniff J; Levin MJ
    Lancet Infect Dis; 2016 Aug; 16(8):915-22. PubMed ID: 27061887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
    Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
    Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.
    Weinberg A; Canniff J; Rouphael N; Mehta A; Mulligan M; Whitaker JA; Levin MJ
    J Immunol; 2017 Jul; 199(2):604-612. PubMed ID: 28607114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster.
    Ulaszewska M; Merelie S; Sebastian S; Lambe T
    Hum Vaccin Immunother; 2023 Dec; 19(1):2175558. PubMed ID: 36785938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.